Cargando…
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
BACKGROUND: Opioid-induced constipation (OIC) is one of the major symptoms in palliative care with a prevalence of 30-50%. Methylnaltrexone for the treatment of OIC is significantly more effective than placebo, but only in about fifty percent of the patients regardless of dose increase. Dose increas...
Autores principales: | Neefjes, Elisabeth CW, van der Vorst, Maurice JDL, Boddaert, Manon SA, Zuurmond, Wouter WA, van der Vliet, Hans J, Beeker, Aart, van den Berg, Hendrik P, van Groeningen, Cornelis J, Vrijaldenhoven, Suzan, Verheul, Henk MW |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145161/ https://www.ncbi.nlm.nih.gov/pubmed/25165428 http://dx.doi.org/10.1186/1472-684X-13-42 |
Ejemplares similares
-
Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008) -
Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
por: Deibert, Peter, et al.
Publicado: (2010) -
Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting
por: Saini, Harneel S, et al.
Publicado: (2020) -
Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide
por: Bader, S., et al.
Publicado: (2011) -
Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
por: Clemens, Katri Elina, et al.
Publicado: (2010)